Morning Overview on MSN
CRISPR approach targets mitochondria to aid heart failure treatment
Rice University researchers have developed a CRISPR-based gene activation strategy that boosts mitochondrial production in damaged heart cells, improving cardiac function after heart attacks in both ...
Morning Overview on MSN
Gene editing advances raise real prospects for future DNA upgrades
The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...
The global CRISPR technology market is anticipated to grow at a robust compound annual growth rate of approximately 16% over the next five years. This rapid expansion is driven by continuous ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
This includes the labeling of the dCas9 protein, engineering of sgRNA, and the use of dCas9 orthologs from different bacterial species. CRISPR, clustered regularly interspaced short palindromic ...
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results